Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

NCT01092585 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
27
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Genta Incorporated